NCT04251182View on ClinicalTrials.gov

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

January 20, 2023

Study Completion Date

February 17, 2023

Conditions
Alzheimer Disease
Interventions
DRUG

15mg T3D-959

Oral administration once daily in the morning

DRUG

30 mg T3D-959

Oral administration once daily in the morning

DRUG

45 mg T3D-959

Oral administration once daily in the morning

DRUG

Placebos

Oral administration once daily in the morning

Trial Locations (1)

27709

T3D Therapeutics, Durham

Sponsors

Collaborators (1)

Clinilabs, Inc.
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Clinilabs, Inc.

OTHER

collaborator

Alzheimer's Association

OTHER

lead

T3D Therapeutics, Inc.

INDUSTRY

NCT04251182 - Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects | Biotech Hunter | Biotech Hunter